Phage Therapy Pharmacology

被引:160
|
作者
Abedon, Stephen T. [1 ]
Thomas-Abedon, Cameron [1 ]
机构
[1] Ohio State Univ, Dept Microbiol, Mansfield, OH 44906 USA
关键词
Bacteriophages; ecology; pharmacodynamics; pharmacokinetics; INFECTIOUS-DISEASES-SOCIETY; BACTERIOPHAGE THERAPY; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; BACTERIAL BIOFILMS; LYSIS-INHIBITION; RESISTANT; KINETICS; REMOVAL;
D O I
10.2174/138920110790725410
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phage therapy-application of bacteria-specific viruses to reduce densities of pathogenic or nuisance bacteria-is a two-step process involving phage penetration to target bacteria followed by bacteria killing. Any analysis of these steps is inherently ecological as they represent phage-environment interactions, i.e., between phages and bacteria as well as between phages and body tissues. In considering phages more generically, as selectively toxic antibacterial agents employed to treat bacterial infections, the term "ecology" may be fairly cleanly replaced with the term "pharmacology". Pharmacology, in turn, may be distinguished into two major components: pharmacokinetics and pharmacodynamics. Pharmacokinetics is explicitly a description of the body's impact on a drug (e.g., movement through and between body compartments) whereas pharmacodynamics is a description of a drug's impact on the body. "Body" includes both body tissues and microbial flora, so an important component of antibacterial pharmacodynamics is inhibition of the growth of target bacteria. Our guiding premise is that phage therapy may be rationally improved through a better understanding of phage pharmacokinetics and pharmacodynamics. Our primary conclusions are (i) that the principle advantages of phages, over antibiotics, are the former's relative safety and ease of discovery; (ii) that phage therapy efficacy is highly dependent on attaining relatively high phage "killing titers"; (iii) that attainment of sufficient titers solely via in situ phage replication should, in some or many circumstances, not be counted upon; and (iv) that phage replication nonetheless may provide a "margin of safety" toward attaining phage therapy efficacy.
引用
收藏
页码:28 / 47
页数:20
相关论文
共 50 条
  • [21] The dawn of phage therapy
    Rehman, Sana
    Ali, Zahid
    Khan, Momna
    Bostan, Nazish
    Naseem, Saadia
    REVIEWS IN MEDICAL VIROLOGY, 2019, 29 (04)
  • [22] Phage therapy for IBD
    Burke, Maria
    CHEMISTRY & INDUSTRY, 2022, 86 (09) : 6 - 6
  • [23] Phage therapy in IBD
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 624 - 624
  • [24] The epic of phage therapy
    Dublanchet, Alain
    Bourne, Shawna
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2007, 18 (01): : 15 - 18
  • [25] Phage therapy, an alternative to antibiotic therapy?
    Reina, Jordi
    Reina, Nuria
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2018, 31 (02) : 101 - 104
  • [26] Improving phage therapy by evasion of phage resistance mechanisms
    Bleriot, Ines
    Pacios, Olga
    Blasco, Lucia
    Fernandez-Garcia, Laura
    Lopez, Maria
    Ortiz-Cartagena, Concha
    Barrio-Pujante, Antonio
    Garcia-Contreras, Rodolfo
    Pirnay, Jean-Paul
    Wood, Thomas K.
    Tomas, Maria
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 6 (01):
  • [27] Synergy as a rationale for phage therapy using phage cocktails
    Schmerer, Matthew
    Molineux, Ian J.
    Bull, James J.
    PEERJ, 2014, 2
  • [28] ALTERNATIVES TO ANTIBIOTICS: PHAGE LYTIC ENZYMES AND PHAGE THERAPY
    Nazarov, P. A.
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2018, (01): : 5 - 15
  • [29] Models of virulent phage growth with application to phage therapy
    Smith, Hal L.
    SIAM JOURNAL ON APPLIED MATHEMATICS, 2008, 68 (06) : 1717 - 1737
  • [30] Phage Neutralization by Sera of Patients Receiving Phage Therapy
    Lusiak-Szelachowska, Marzanna
    Zaczek, Maciej
    Weber-Dabrowska, Beata
    Miedzybrodzki, Ryszard
    Klak, Marlena
    Fortuna, Wojciech
    Letkiewicz, Slawomir
    Rogoz, Pawel
    Szufnarowski, Krzysztof
    Jonczyk-Matysiak, Ewa
    Owczarek, Barbara
    Gorski, Andrzej
    VIRAL IMMUNOLOGY, 2014, 27 (06) : 295 - 304